UroToday2d
Clarity enters a Clinical Manufacturing Agreement for Cu-64 SAR-bisPSMA with SpectronRx
Reno, Nevada (UroToday.com) Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve ...
UroToday3d
Clinical Implications of the Molecular and Genomic Landscape of Upper Tract Urothelial Carcinoma.
Upper tract urothelial carcinoma (UTUC) is an aggressive entity with treatment strategies mirroring bladder cancer. Genomic and molecular profiling allows for a better characterization of this disease ...
UroToday3d
Impact of DNA Repair Deficiency in the Evolving Treatment Landscape of Bladder Cancer.
This review explores the current landscape of treatments which target the DNA damage response (DDR) in metastatic and muscle-invasive bladder cancer. It emphasizes recent clinical trials which ...
UroToday3d
Discovery of a Highly Potent PROTAC Degrader of p300/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer.
Prostate cancer therapies against androgen receptor (AR) eventually develop lethal resistance; thus, exploring new therapeutic approaches is urgent for prostate cancer treatment. Acetyltransferase ...
UroToday3d
Perioperative Complications and In-Hospital Mortality in Paraplegic Radical Cystectomy Patients.
The aim of this study was to test for the association between paraplegia and perioperative complications as well as in-hospital mortality after radical cystectomy (RC) for non-metastatic bladder ...
UroToday3d
Setting the Stage: Feasibility and Baseline Characteristics in the PARTIQoL Trial Comparing Proton Therapy vs. IMRT for Localized Prostate Cancer.
Men with localized prostate cancer may receive either photon-based intensity-modulated radiotherapy (IMRT) or proton beam therapy (PBT). The XXXXX trial (NCT01617161), demonstrates the feasibility of ...
UroToday3d
Dose-escalated Adaptive Radiotherapy for Bladder Cancer: Results of the Phase 2 RAIDER Randomised Controlled Trial.
Delivering radiotherapy to the bladder is challenging as it is a mobile, deformable structure. Dose-escalated adaptive image-guided radiotherapy could improve outcomes. RAIDER aimed to demonstrate the ...
UroToday4d
Disparities and Underutilization of Aggressive Therapy in Muscle-Invasive Bladder Cancer: An NCDB Analysis
Ashish Kamat and Siamak Daneshmand discuss research on racial differences in tumor detection using blue light cystoscopy. The study reveals that while blue light enhances tumor detection universally, ...
UroToday4d
Multiplex Imaging of Localized Prostate Tumors Reveals Altered Spatial Organization of AR-Positive Cells in the Microenvironment - Beyond the Abstract
Our recent investigation into the spatial cellular landscape of localized prostate tumors provides a comprehensive analysis of over 20 androgen receptor (AR)-positive immune and non-immune stromal ...
UroToday4d
Instrument Failures for the AirSeal device: a Food and Drug Administration MAUDE Database Study
Objective: This study aims to analyze instances of AirSeal device failures reported in the Food and Drug Administration's MAUDE (Manufacturer and User Facility Device) database, focusing on ...
UroToday4d
Early Adjuvant Chemotherapy Improves Survival in Muscle Invasive Bladder Cancer: A Systematic Review and Meta-analysis - Beyond the Abstract
Muscle-invasive bladder cancer (MIBC) requires an aggressive treatment strategy that typically involves neoadjuvant chemotherapy (NAC) followed by radical cystectomy with pelvic lymph node dissection.
UroToday4d
Synthetic Lethal Targeting of Cyclin Dependent Kinase-12-Deficient Prostate Cancer with PARP Inhibitors.
CDK12 is a cyclin-dependent kinase (CDK) that is mutated or amplified in multiple cancers. We previously described a subtype of prostate cancer (PC) characterized predominantly by frameshift, ...